Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-19

FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for the generic fixed-dose combination of carbidopa, levodopa, and entacapone by Sandoz Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carbidopa, Levodopa and Entacapone (carbidopa/levodopa/entacapone)

Snippet

SUPPL AP for CARBIDOPA, LEVODOPA, AND ENTACAPONE (CARBIDOPA, LEVODOPA, AND ENTACAPONE)